Biogen’s lack of insider buying and reduced R&D spending raise concerns, but its future growth prospects remain. Find out why ...

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the ...

While a long-term play, the new agreement is a further sign of Biogen's efforts to rebuild its pipeline after admitting that Aduhelm (aducanumab) will not make any commercial contribution anytime ...

Biogen Inc. closed 49.79% below its 52-week high of $238.00, which the company achieved on July 12th.

there are other factors that are even more important. Case in point: We've spotted 1 warning sign for Biogen you should be aware of.

Biogen Inc. closed 51.05% below its 52-week high of $238.00, which the company reached on July 12th.